We need to think beyond the $440K licence fee receipt and consider how this test will enable midkine to sit as a co-marker for all the other cancer diagnostic tests out there.
H U G E !
cheers
- Forums
- ASX - By Stock
- AN1
- fujikura exercises its option to license cellm
fujikura exercises its option to license cellm, page-3
-
- There are more pages in this discussion • 50 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add AN1 (ASX) to my watchlist
|
|||||
Last
0.8¢ |
Change
0.000(0.00%) |
Mkt cap ! $3.690M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
AN1 (ASX) Chart |
Day chart unavailable